ELISA measurements for "Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogeneity in disease phenotype"

ELISA measurements from plasma samples were carried out using the Ciraplex® platform (Aushon Biosystems, Billerica, MA, US). Commercial assays were purchased and measurements were carried out according to instructions provided by the manufacturer. The following 29 targets were analyzed either as single-plex assays or as multiplex assay: hFGFb; hGROa; hLIF;hIFNg; hIL1b; IL4; IL5; hIL6; hIL10; hIL12p70; hIL13; hTNFa; hI309; hIL8; hIP10; hMCP4; hMIP1a; hMIP1b; hCRP; hLeptin; hPAIactive; hResistin; hIGFBP1; hIGFBP3; hIGFBP2; hMIF; hApoA1; hCRP; hAcrp30.

本研究采用Ciraplex®平台（美国马萨诸塞州比勒里卡市Aushon Biosystems公司）对血浆样本开展酶联免疫吸附试验（Enzyme-Linked Immunosorbent Assay，ELISA）检测。所用商业化检测试剂盒均为外购商品，并严格按照对应制造商提供的操作说明书完成检测操作。本次共分析29种靶标，分别以单重检测（single-plex assays）或多重检测（multiplex assay）形式进行，具体靶标如下：hFGFb、hGROa、hLIF、hIFNg、hIL1b、IL4、IL5、hIL6、hIL10、hIL12p70、hIL13、hTNFa、hI309、hIL8、hIP10、hMCP4、hMIP1a、hMIP1b、hCRP、hLeptin、hPAIactive、hResistin、hIGFBP1、hIGFBP3、hIGFBP2、hMIF、hApoA1、hCRP、hAcrp30。